By investigating the role of the proteins TBX2 and KDM1A in breast cancer, Dr Mullan’s team aims to reveal which patients are likely to fail to respond to current chemotherapy treatments and provide an opportunity for the development of new targeted treatments, including treatments for triple negative breast cancers.


Dr McIntyre will study the mechanisms that allow triple negative breast cancer cells to survive when oxygen levels are low. This will help to identify the most effective way to treat patients with triple negative breast cancer.

Dr Triona Ni Chonghaile aims to understand the role of the bromodomain proteins in the progression of invasive lobular breast cancer, a subtype of breast cancer that occurs in 15% of cases. The researchers aim to investigate if a small molecule drug, JQ1, can target the bromodomain proteins and stop lobular breast cancer’s growth.   


Dr Khaled will be researching how BCL11A and other proteins interact in triple negative breast cancer cells and how these interactions affect the rest of the cell. He hopes that this information could lead to new targeted treatments for this form of the disease.



Dr Fiona Kennedy will investigate the feasibility of an online resource to offer support to secondary breast cancer patients and help them to manage their symptoms with the ultimate aim of improving their overall quality of life.

Dr Anna Git will be studying the role of molecules called mid-sized non-coding RNAs, which she believes could have a more important role in breast cancer than previously thought. Her work will lead to a better understanding of breast cancer, and hopefully improved treatments.